Our network pharmacology analysis and experimental validation converged on the NF-κB signaling pathway as the central mechanistic node mediating LCD’s therapeutic effects, consistent with extensive evidence demonstrating NF-κB hyperactivation in both lupus nephritis and OP pathogenesis (46, 47). This evidence concerns the gene NFKB1 and lupus nephritis.